Irisawa, Ai
Takeno, Misaki
Watanabe, Kazuo
Takahashi, Hideaki
Mitsunaga, Shuichi
Ikeda, Masafumi
Article History
Received: 2 February 2022
Accepted: 17 August 2022
First Online: 16 September 2022
Competing interests
: M.I reports personal fees and other from Chugai, other from Yakult, personal fees and other from Nihon Servier, other from Ono, other from Bristol-Myers Squibb, personal fees from Taiho, personal fees from AstraZeneca, other from Novartis, and other from Delta-Fly Pharma, during the conduct of the study; personal fees and other from Bayer, personal fees and other from Eisai, other from Merck Serono, personal fees and other from MSD, other from J-Pharma, personal fees from Teijin Pharma, personal fees from Astellas, personal fees and other from EA Pharma, other from Pfizer, other from Chiome Bioscience, personal fees and other from ASLAN, personal fees from Sumitomo Dainippon, personal fees from Gilead, personal fees from Otsuka, other from GlaxoSmithKline, outside the conduct of the study. The other authors declare no potential conflict of interest.